Evidence map›Paper›PMID 42154338›Full record

ArticleMetabolic brain disease2026

Tirzepatide attenuates neurotoxicity by suppressing inflammation, apoptosis and restoring neurotrophin expression in an Alzheimer's disease-like rat model.

Mohamed S M Attia, Sheikh F Ahmad, Ahmed Nadeem, Mushtaq A Ansari, Mohammed A Al-Hamamah, Gamaleldin I Harisa, Saleh A Bakheet, Talha Bin Emran, Tanveer Singh, Sabry M Attia

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohamed S M AttiaDepartment of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmacy, Egyptian Russian University, Cairo, 11829, Egypt.ORCID 0009-0002-3623-1137
Sheikh F AhmadDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.ORCID 0000-0002-8282-3726
Ahmed NadeemDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.ORCID 0000-0003-2038-8367
Mushtaq A AnsariDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.ORCID 0000-0002-3556-5939
Mohammed A Al-HamamahDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.ORCID 0000-0001-7424-0910
Gamaleldin I HarisaDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.ORCID 0000-0002-7988-4421
Saleh A BakheetDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.ORCID 0000-0003-2008-6377
Talha Bin EmranDepartment of Pharmacy, Faculty of Health and Life Sciences,, Daffodil International University, Dhaka, 1216, Bangladesh.ORCID 0000-0003-3188-2272
Tanveer SinghDepartment of Molecular and Integrative Physiology, University of Illinois at Urbana- Champaign, 407 South Goodwin Avenue, 524 Burrill Hall, Urbana, IL, 61801, USA.ORCID 0000-0002-9038-8082
Sabry M AttiaDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia. attiasm@ksu.edu.sa.ORCID 0000-0001-8560-8944

Funding

King Saud University ORF-2026-748
6 · The paper itself

Abstract

backgroundDespite numerous milestones in Alzheimer's disease (AD) research, the disease remains incurable, with a high prevalence and significant financial burdens. As a result, researchers are keen to look for new medications that can help manage or prevent the disease. MATERIALS AND

methodsThe effects of long-term exposures to tirzepatide, a novel dual GIP/GLP-1 receptor agonist, on neurotoxicity and behavioral changes in the D-galactose/aluminium chloride (D-gal/AlCl RESULTS AND

conclusionThe present findings show that long-term administration of tirzepatide effectively reduced D-gal/AlCl

Indexed as

Alzheimer DiseaseApoptosisInflammationNeuroprotective AgentsTirzepatideAmyloid beta-PeptidesAnimalsDisease Models, AnimalMaleRatsRats, Sprague-DawleyAmyloid beta-PeptidesNeuroprotective AgentsTirzepatideNeurodegenerative diseaseNeuroinflammationPharmacotherapy incretin mimeticTirzepatide

Identifiers

PMID42154338

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.